Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ Quantitative Report
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Transition Therapeutics Inc enters into a private placement with investors to receive up to $30.8 mln in equity financing


Friday, 6 Jun 2014 09:01am EDT 

Transition Therapeutics Inc:Says Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders will make an investment of up to $30.8 mln.Says by purchasing 3,195,487 units of the company at a price of $5.32 per unit.Each unit consists of one common share, and 0.61 of a common share purchase warrant with a purchase price of $7.10 per whole warrant.Each whole warrant will entitle the holder, within two years from closing, to purchase one additional common share in the capital of the Company.If and when all of the warrants are exercised, the Company will realize an additional $13.8 mln, bringing the total investment to $30.8 mln before transaction costs.Closing of the private placement is expected to occur on or about June 20 and is subject to approval from the Toronto Stock Exchange. 

Company Quote

8.08
 --
23 Dec 2014